How Long Does Rapamycin Stay in Your System? What the Literature Describes

Short answer: rapamycin (sirolimus) is not a peptide, and its disposition looks nothing like the injectable peptides that dominate this topic. It is a macrolide small molecule that binds FKBP12, distributes heavily into red blood cells, is metabolised by CYP3A enzymes and transported by P-glycoprotein, and carries a terminal half-life described in approved product labelling in tens of hours rather than minutes. That means measurable blood concentrations persist for days after a single exposure, and steady-state accumulation occurs with repeated exposure. This page summarises what the published literature in the reference list actually measured, and states plainly where the numbers come from labelling and general pharmacology rather than from those papers.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or laboratory test. Nothing here describes how any substance should be used.

Why rapamycin is the odd one out in a "peptide half-life" discussion

Most compounds covered in the peptide clearance guide are short chains of amino acids. Peptides are generally cleaved by peptidases in plasma and tissue, filtered or catabolised by the kidney, and cleared within minutes to a few hours unless the molecule has been engineered with fatty-acid acylation, PEGylation or albumin binding. Rapamycin does not belong to that class at all. It is a lipophilic macrolide lactone produced by Streptomyces hygroscopicus, and it is handled by the cytochrome P450 system and biliary excretion rather than by proteolysis.

That distinction matters for interpreting any timing question. A 2023 Gerontology article argued that rapamycin and its synthetic analogues should not be treated as interchangeable, describing pharmacological differences between the parent molecule and the rapalog class (PMID 36617414). The practical implication of that argument is that half-life figures, exposure profiles and dosing intervals reported for one rapalog cannot simply be transferred onto rapamycin, and vice versa — a point that is routinely blurred in secondary summaries.

What "half-life" describes, and what labelling reports

Half-life is the time required for blood concentration to fall by half during the elimination phase. It is not the time at which a drug stops acting, and for rapamycin the gap between the two is unusually wide, because the molecule binds FKBP12 intracellularly and its downstream effect on mTORC1 signalling can outlast the plasma curve.

Approved sirolimus product labelling — a regulatory document, not one of the studies cited on this page — describes a mean terminal half-life in stable adult transplant recipients of roughly 62 hours, with extensive sequestration in erythrocytes, which is why sirolimus concentrations are monitored in whole blood rather than plasma. Labelling also describes CYP3A4 metabolism, P-glycoprotein transport, and predominantly faecal excretion. None of the verified papers below measured or reported those pharmacokinetic parameters, and this page does not attribute them to those papers.

Illustrative clearance arithmetic

The table below applies the standard pharmacokinetic convention that about 97% of a dose is eliminated after five half-lives. It is arithmetic applied to the labelled figure above, not a measurement from any cited study, and individual values vary widely.

Two caveats follow from the arithmetic itself. First, a long half-life means repeated administration accumulates, and steady state is not reached for roughly five half-lives — which is why clinical monitoring of sirolimus uses trough concentrations taken after several days of consistent exposure. Second, the terminal half-life reported in stable transplant recipients is not a universal constant; it shifts with liver function, age, co-medication and formulation.

What the verified studies actually measured

A recurring problem in this topic is that rapamycin appears in hundreds of biology papers as a tool compound, and readers assume those papers characterised its clearance. Mostly they did not — they dosed it and then measured a biological endpoint. The studies in the reference list illustrate that pattern.

A 2014 Neuron study reported that loss of mTOR-dependent macroautophagy produced autistic-like synaptic pruning deficits in mice and that rapamycin corrected the pruning and behavioural phenotypes in that model (PMID 25155956). A 2013 review in the Journal of Biochemical and Pharmacological Research discussed rapamycin, autophagy induction and Alzheimer's disease models (PMID 23826514). A 2018 report in Autophagy examined autophagy-targeting strategies, rapamycin among them, in the setting of hyperammonemia (PMID 30035657). Each reported biological outcomes; none of these papers was a human pharmacokinetic study, and none supplied a half-life value that could be generalised.

Intermittent dosing as a timing signal

The closest the verified set comes to a timing argument is the cell-therapy literature, where rapamycin is used as a pharmacological switch and the schedule therefore has to respect how long the drug persists. A 2024 Journal of Clinical Investigation study reported that CD33-targeted CAR T cells could be controlled with clinically optimized rapamycin dosing to treat acute myeloid leukaemia in preclinical models (PMID 38502193). Related work in Molecular Therapy reported that regulated BCMA CAR T cells eliminated circulating antibodies in humanized mice (PMID 39673129), and a 2025 Journal of Clinical Investigation study reported that rapamycin enhanced CAR-T control of HIV replication and reservoir elimination in vivo (PMID 39932788). The researchers in these programmes designed schedules around sustained systemic exposure — a drug that vanished within hours could not serve as an on/off control in the way those studies described.

Detectability: what is and is not tested for

Standard drug panels

Routine workplace, pre-employment and forensic urine panels are built to detect drugs of abuse — typically amphetamines, cocaine metabolites, opiates, phencyclidine and cannabinoids, with expanded panels adding benzodiazepines, barbiturates, methadone and oxycodone. Sirolimus is not an analyte on those panels. It is an immunosuppressant, not a controlled substance of abuse, and an immunoassay designed for amphetamine class compounds does not cross-react with a macrolide lactone. In plain terms: a standard drug screen is not looking for rapamycin and would not report it.

Assays that do detect it

Sirolimus is detected and quantified by dedicated therapeutic drug monitoring assays used in transplant medicine. These are whole-blood assays — because of erythrocyte partitioning — run either as specific immunoassays or by liquid chromatography–tandem mass spectrometry (LC-MS/MS). They are ordered deliberately, not incidentally, and they report a concentration in ng/mL rather than a positive/negative result. A general metabolic panel, complete blood count or standard toxicology screen does not include them.

Anti-doping context

Anti-doping testing is governed by a published prohibited list that is revised annually; substances are screened for only when they appear on that list or fall within a listed class. Athletes subject to testing are generally advised by their governing body's medical officers on which agents require a therapeutic use exemption. This page does not attempt to summarise current list status, which changes, and none of the verified studies below addressed doping control.

Factors that change how fast rapamycin clears

The variables below are drawn from general pharmacology and from approved sirolimus labelling, not from the cited study set, and are listed for orientation only.

• CYP3A4 and CYP3A5 activity. Rapamycin is a CYP3A substrate, so strong inhibitors (for example azole antifungals, macrolide antibiotics, some protease inhibitors, grapefruit juice) raise exposure, while strong inducers (rifampicin, certain anticonvulsants, St John's wort) lower it.
• P-glycoprotein transport. Efflux at the gut wall shapes oral bioavailability, so P-gp modulators shift both absorption and elimination.
• Hepatic function. Because clearance is largely hepatic, impaired liver function prolongs the terminal half-life; sirolimus labelling describes dose considerations in hepatic impairment.
• Haematocrit and erythrocyte binding. Whole-blood concentrations depend on red-cell mass, one reason whole blood, not plasma, is the monitoring matrix.
• Formulation. Tablet, oral solution, nanoparticle and topical formulations do not produce equivalent systemic exposure profiles.

On the last point, a 2022 Nanomaterials study reported a safety evaluation of rapamycin perfluorocarbon nanoparticles in the context of preventing cisplatin-induced kidney injury (PMID 35159680). The relevance to a clearance question is structural rather than numerical: encapsulating a lipophilic drug in a carrier changes where it distributes and how it is eliminated, so half-life figures from conventional oral sirolimus cannot be assumed to describe a nanoparticle preparation.

Rapamycin Tolerability: What Studies Report

The verified set is weighted toward mechanism and preclinical efficacy rather than systematic safety reporting, and the page does not extrapolate beyond it. The 2022 Nanomaterials study was framed explicitly around the safety profile of a rapamycin nanoparticle formulation in a kidney-injury prevention model (PMID 35159680). In the cell-therapy work, rapamycin was administered as a regulatory input to control engineered T cells, and the 2024 CD33 CAR T study reported that clinically optimized dosing was used to achieve that control in preclinical models (PMID 38502193). The 2023 Gerontology article's argument that rapamycin and rapalogs behave differently also applies to tolerability claims, which should not be pooled across the class (PMID 36617414). Immunosuppression, metabolic effects and infection risk are documented in approved product labelling for sirolimus and are matters for a prescribing clinician.

What the evidence here does not establish

1. No paper in this reference set reported a human half-life, clearance rate or time-to-undetectable value for rapamycin.
2. Biological effects on mTOR and autophagy, such as those reported in the 2014 Neuron mouse study (PMID 25155956), do not map one-to-one onto blood concentration curves.
3. Preclinical models — mice, humanized mice, cell systems — metabolise CYP3A substrates differently from humans, so animal timing data do not transfer directly, including from the HIV CAR-T work (PMID 39932788).

Related reading

• Rapamycin: what the literature covers
• How long do peptides stay in your system?

References

• Why Is Rapamycin Not a Rapalog? (Gerontology, 2023)
• Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing (The Journal of Clinical Investigation, 2024)
• Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo (The Journal of Clinical Investigation, 2025)
• Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice (Molecular Therapy, 2025)
• Safety Profile of Rapamycin Perfluorocarbon Nanoparticles for Preventing Cisplatin-Induced Kidney Injury (Nanomaterials, 2022)
• Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits (Neuron, 2014)
• Rapamycin, Autophagy, and Alzheimer's Disease (Journal of Biochemical and Pharmacological Research, 2013)
• Targeting autophagy for therapy of hyperammonemia (Autophagy, 2018)